Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
HPB (Oxford) ; 25(5): 568-576, 2023 05.
Article in English | MEDLINE | ID: mdl-36804057

ABSTRACT

BACKGROUND: Bacterial infection is common in acute cholecystitis (AC). To identify appropriate empirical antibiotics, we investigated AC-associated microorganisms and their susceptibilities to antibiotics. We also compared preoperative clinical findings of patients grouped according to specific microorganisms. METHODS: Patients who underwent laparoscopic cholecystectomy for AC between 2018 and 2019 were enrolled. Bile cultures and antibiotic susceptibility tests were performed, and clinical findings of patients were noted. RESULTS: A total of 282 patients were enrolled (147 culture-positive and 135 culture-negative). The most frequent microorganisms were Escherichia (n = 53, 32.7%), Enterococcus (n = 37, 22.8%), Klebsiella (n = 28, 17.3%), and Enterobacter (n = 18, 11.1%). For Gram-negative microorganisms, second-generation cephalosporin (cefotetan: 96.2%) was more effective than third-generation cephalosporin (cefotaxime: 69.8%). Vancomycin and teicoplanin (83.8%) were the most effective antibiotics for Enterococcus. Patients with Enterococcus had higher rates of CBD stones (51.4%, p = 0.001) and biliary drainage (81.1%, p = 0.002), as well as higher levels of liver enzymes, than patients with other microorganisms. Patients with ESBL-producing bacteria had higher rates of CBD stones (36.0% vs. 6.8%, p = 0.001) and biliary drainage (64.0% vs. 32.4%, p = 0.005) than those without. DISCUSSION: Preoperative clinical findings of AC are related to microorganisms in bile samples. Periodic antibiotic susceptibility tests should be conducted to select appropriate empirical antibiotics.


Subject(s)
Bacterial Infections , Cholecystitis, Acute , Humans , Anti-Bacterial Agents/therapeutic use , Bile/microbiology , Cholecystitis, Acute/diagnosis , Cholecystitis, Acute/drug therapy , Cholecystitis, Acute/surgery , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Cefotaxime , Enterococcus
2.
Nucleic Acids Res ; 48(1): 130-140, 2020 01 10.
Article in English | MEDLINE | ID: mdl-31713617

ABSTRACT

Charcot-Marie-Tooth 1A (CMT1A) is the most common inherited neuropathy without a known therapy, which is caused by a 1.4 Mb duplication on human chromosome 17, which includes the gene encoding the peripheral myelin protein of 22 kDa (PMP22). Overexpressed PMP22 protein from its gene duplication is thought to cause demyelination and subsequently axonal degeneration in the peripheral nervous system (PNS). Here, we targeted TATA-box of human PMP22 promoter to normalize overexpressed PMP22 level in C22 mice, a mouse model of CMT1A harboring multiple copies of human PMP22. Direct local intraneural delivery of CRISPR/Cas9 designed to target TATA-box of PMP22 before the onset of disease, downregulates gene expression of PMP22 and preserves both myelin and axons. Notably, the same approach was effective in partial rescue of demyelination even after the onset of disease. Collectively, our data present a proof-of-concept that CRISPR/Cas9-mediated targeting of TATA-box can be utilized to treat CMT1A.


Subject(s)
Charcot-Marie-Tooth Disease/therapy , Molecular Targeted Therapy/methods , Myelin Proteins/genetics , Myelin Sheath/metabolism , Schwann Cells/metabolism , TATA Box , Animals , Axons , CRISPR-Cas Systems , Charcot-Marie-Tooth Disease/genetics , Charcot-Marie-Tooth Disease/metabolism , Charcot-Marie-Tooth Disease/pathology , Chromosome Duplication , Chromosomes, Human, Pair 17 , Disease Models, Animal , Gene Editing/methods , Humans , Injections , Mice , Myelin Proteins/metabolism , Myelin Sheath/pathology , Primary Cell Culture , Promoter Regions, Genetic , Schwann Cells/pathology , Sciatic Nerve/metabolism , Sciatic Nerve/pathology
3.
J AAPOS ; 18(2): 183-4, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24698618

ABSTRACT

Eyedrops used for mydriasis and cycloplegia can be systemically absorbed, causing serious side effects, including oxygen desaturation, apnea, bradycardia, transient hypertension, delayed gastric emptying, and transient paralytic ileus. These effects can be more serious in infants because of their lower body mass and immature cardiovascular and nervous systems. We report a case of a 27-week-old infant who suffered a cardiopulmonary arrest after the administration of only Cyclomydril eyedrops (Alcon Laboratories, Fort Worth, TX) during an outpatient retinopathy of prematurity examination.


Subject(s)
Cyclopentolate/adverse effects , Heart Arrest/chemically induced , Mydriatics/adverse effects , Phenylephrine/adverse effects , Retinopathy of Prematurity/diagnosis , Cardiopulmonary Resuscitation , Drug Combinations , Female , Gestational Age , Heart Arrest/therapy , Humans , Infant , Ophthalmic Solutions , Outpatients
4.
Curr Cancer Drug Targets ; 13(8): 867-78, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23822752

ABSTRACT

Hepatocellular cancer (HCC) is the third cause of death by cancer worldwide. In the current study we target ß- catenin, an oncogene mutated and constitutively active in 20-30% of HCCs, via a novel, cell permeable gamma guanidine-based peptide nucleic acid (γGPNA) antisense oligonucleotide designed against either the transcription or the translation start site of the human ß-catenin gene. Using TOPflash, a luciferase reporter assay, we show that γGPNA targeting the transcription start site showed more robust activity against ß-catenin activity in liver tumor cells that harbor ß-catenin gene mutations (HepG2 & Snu-449). We identified concomitant suppression of ß-catenin expression and of various Wnt targets including glutamine synthetase (GS) and cyclin-D1. Concurrently, γGPNA treatment reduced proliferation, survival and viability of HCC cells. Intriguingly, an angiogenesis quantitative Real-Time-PCR array identified decreased expression of several pro-angiogenic secreted factors such as EphrinA1, FGF-2, and VEGF-A upon ß-catenin inhibition in liver tumor cells. Conversely, transfection of stabilized-ß-catenin mutants enhanced the expression of angiogenic factors like VEGF-A. Conditioned media from HepG2 cells treated with ß-catenin but not the mismatch γGPNA significantly diminished spheroid and tubule formation by SK-Hep1 cells, an HCC-associated endothelial cell line. Thus, we report a novel class of cell permeable and efficacious γGPNAs that effectively targets ß-catenin, a known oncogene in the liver. Our study also identifies a novel role of ß-catenin in liver tumor angiogenesis through paracrine mechanisms in addition to its roles in proliferation, survival, metabolism and cancer stem cell biology, thus further strengthening its effectiveness as a therapeutic target in HCC.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Cell-Penetrating Peptides/pharmacology , Guanidine/chemistry , Liver Neoplasms/drug therapy , Peptide Nucleic Acids/pharmacology , beta Catenin/antagonists & inhibitors , Angiogenic Proteins/genetics , Angiogenic Proteins/metabolism , Apoptosis/drug effects , Blotting, Western , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Cell Proliferation/drug effects , Cell-Penetrating Peptides/chemistry , Gene Knockdown Techniques , Humans , Liver Neoplasms/genetics , Liver Neoplasms/pathology , Luciferases/metabolism , Neovascularization, Pathologic , Peptide Nucleic Acids/chemistry , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Transcription Initiation Site , Tumor Cells, Cultured , beta Catenin/genetics
5.
Mediators Inflamm ; 2012: 948367, 2012.
Article in English | MEDLINE | ID: mdl-22988347

ABSTRACT

There is evidence of intestinal inflammation in patients with CF. Intestinal inflammation may negatively impact the nutritional status of patient with CF, which adversely affects pulmonary function and survival. This paper provides an up-to-date review of intestinal inflammation in CF and an evaluation of utility of two specific faecal inflammatory markers (S100A12 and calprotectin).


Subject(s)
Biomarkers/metabolism , Cystic Fibrosis/immunology , Cystic Fibrosis/metabolism , Feces/chemistry , Inflammation/metabolism , Humans , Inflammation/immunology , Leukocyte L1 Antigen Complex/metabolism , S100 Proteins/metabolism , S100A12 Protein
6.
Biochem Biophys Res Commun ; 398(3): 372-6, 2010 Jul 30.
Article in English | MEDLINE | ID: mdl-20599725

ABSTRACT

Podocalyxin, an integral plasma membrane cell-adhesion glycoprotein, is a marker of human pluripotent and multipotent stem cells. Podocalyxin is also a marker of many types of cancers and its expression correlates with an aggressive and poor-prognosis tumor phenotype. The function of podocalyxin in stem cells and malignant cells is unknown. Protein sequence data obtained from purified podocalyxin protein isolated from embryonal carcinoma cancer stem cells reveals peptide sequence data for the glucose-3-transporter. Protein-precipitation experiments of embryonal carcinoma protein extracts identify a podocalyxin/glucose-3-transporter protein complex. Cell imaging studies demonstrate co-localization of podocalyxin and glucose-3-transporter and confirm the interaction in vivo. Finally, siRNA podocalyxin-knockdown experiments show decreased expression levels of the glucose-3-transporter. These findings suggest a novel interaction of the glucose-3-transporter and the cell-adhesion protein podocalyxin. In pluripotent stem cells and in human cancer disease, podocalyxin may function in part to regulate and maintain the cell surface expression of the glucose-3-transporter.


Subject(s)
Biomarkers, Tumor/metabolism , Glucose Transporter Type 3/metabolism , Neoplasms/metabolism , Neoplastic Stem Cells/metabolism , Pluripotent Stem Cells/metabolism , Sialoglycoproteins/metabolism , Amino Acid Sequence , Cell Line, Tumor , Gene Knockdown Techniques , Humans , RNA, Small Interfering/genetics , Sialoglycoproteins/genetics
7.
Nat Med ; 11(1): 95-101, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15619629

ABSTRACT

Molecular profiling of human biopsies and surgical specimens is frequently complicated by their inherent biological heterogeneity and by the need to conserve tissue for clinical diagnosis. We have developed a set of novel 'tissue print' and 'print-phoresis' technologies to facilitate tissue and tumor-marker profiling under these circumstances. Tissue printing transfers cells and extracellular matrix components from a tissue surface onto nitrocellulose membranes, generating a two-dimensional anatomical image on which molecular markers can be visualized by specific protein and RNA- and DNA-detection techniques. Print-phoresis is a complementary new electrophoresis method in which thin strips from the print are subjected to polyacrylamide gel electrophoresis, providing a straightforward interface between the tissue-print image and gel-based proteomic techniques. Here we have utilized these technologies to identify and characterize markers of tumor invasion of the prostate capsule, an event generally not apparent to the naked eye that may result in tumor at the surgical margins ('positive margins'). We have also shown that tissue-print technologies can provide a general platform for the generation of marker maps that can be superimposed directly onto histopathological and radiological images, permitting molecular identification and classification of individual malignant lesions.


Subject(s)
Prostatic Neoplasms/diagnosis , Proteins , Biomarkers , Humans , Male , Prostate/metabolism , Prostate/pathology , Prostatic Neoplasms/metabolism , Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL